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I shall discuss the work of researchers at Harvard Medical School who came together in the
early 1990s. Scattered across various Harvard-affiliated hospitals and research centers,
these individuals were unified by their interest in ocular neovascularization. Together and
separately, they investigated models of ocular neovascularization, exploring tumor
angiogenesis in eye development and disease.
ª 2014 The Author. Published by Elsevier Inc.Open access under CC BY-NC-ND license. At Boston Children’s Hospital, Judah Folkman instigated the
investigation of ocular angiogenesis as an extension of his
work in tumor angiogenesis. At Beth Israel Deaconess Medical
Center, Harold Dvorak and Don Senger identified a soluble
factor known as vascular permeability factor (VPF).28 Later,
this factor was independently identified as vascular endo-
thelial growth factor (VEGF) by Napoleone Ferrara at Gen-
entech.23 At Massachusetts Eye and Ear Infirmary, EvangelosCC BY-NC-ND license (ht
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Open access underGragoudas and Donald D’Amico provided clinical insight and
leadership. Across Harvard, there were two primary groups
investigating VEGF and ocular angiogenesis. Patricia D’Amore,
Anthony Adamis, David Shima, and I formed one at Boston
Children’s Hospital and the Massachusetts Eye and Ear Infir-
mary. The other was composed of Lloyd Paul Aiello and
George King at Joslin Diabetes Center, later joined by Lois
Smith of Boston Children’s Hospital. Robert D’Amato led antp://creativecommons.org/licenses/by-nc-nd/3.0/).
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angiogenesis. There were, of course, many collaborators,
postdoctoral fellows, and students, without whom the inves-
tigations could not have been carried out.
The search for a secreted factor that stimulated neo-
vascularization dates back to 1948, when Michaelson24
postulated that a soluble and diffusible growth factor (which
became known as the mysterious Factor X) was responsible
for retinal vascular growth in development and disease. In the
1970s, Folkman postulated that angiogenesis, or the growth of
pathologic new vessels, leads to rapid tumor growth.14 Folk-
man’s theory wasmet with skepticism. Interestingly, much of
his work relied on eye models.
In the 1980s, Pat D’Amore, while working with Arnall Patz
and Bert Glaser at Johns Hopkins University, identified the
retina and vitreous as potential sources of angiogenic growth
factors.16e18 D’Amore et al later identified acidic fibroblast
growth factor (aFGF or FGF-1) as an angiogenic factor and
potential candidate for Factor X in ocular neovascularization.9
Over the next several years, several angiogenic factors were
identified.15When basic FGF (bFGF)was found to be elevated in
vitreous samples of patients with diabetic retinopathy,32 it
became one of the leading candidates for Factor X. Impor-
tantly, however, bFGF is not secreted. The identity of Factor X
remained unclear.
Meanwhile, Harold Dvorak and Don Senger at Harvard
Medical School had isolated VPF from ascites fluid and tumor
cell lines and showed that it was 50 times more potent than
histamine as a permeability agent.28 The potent angiogenic
effects of VPF, however, were not appreciated until 1989, when
Napoleone Ferrara of Genentech identified the molecule that
he dubbed VEGF because it led to proliferation of endothelial
cells.23 This proved to be the same molecule as VPF.21 Several
features made VEGF stand out among other candidates for
Factor X. In addition to angiogenesis, VEGF also induced
vascular leakage, another feature of several neovascular
retinal disorders. Importantly, VEGF was secreted in response
to and regulated by hypoxia, a condition believed to stimulate
neovascularization in many retinopathies.
At Folkman’s suggestion, our group initiated some exper-
iments to investigate the role of VEGF in ocular disease, in
collaboration with Dvorak’s team. Adamis, Shima, and
D’Amore first showed that retinal pigment epithelium (RPE)
cells produced VEGF in vitro3 and that this production was
regulated by hypoxia.29,30 At the same time, we began col-
lecting aqueous samples from monkey eyes with experi-
mental retinal ischemia following laser vein occlusion and
demonstrated that VEGF levels correlated with the degree of
neovascularizationdthe first correlation of VEGF with ocular
angiogenesis in vivo.25 Using the samemodel, we were able to
demonstrate that VEGF expression occurred in the inner
retina, which was producing the secreted VEGF121 and
VEGF165 isoforms.31
After associating VEGF with neovascularization in mon-
keys, Adamis and I (in collaboration with D’Amico and Folk-
man) looked to see whether we could associate VEGF with
human ocular disease. We collected vitreous samples from
patients and found that VEGF levels were significantly higher
in eyes with proliferative diabetic retinopathy than thosewithout.1 At the same time, Aiello, working with Ferrara and
a larger collaborative group, collected aqueous and vitreous
specimens frompatients with diabetic retinopathy and retinal
vein occlusion, including specimens obtained before and after
treatment.4 This study provided the strongest evidence thus
far that VEGF protein levels correlatedwith active proliferative
disease in human eyes.
Joined by Smith et al, Aiello then tested soluble VEGF
receptors as an inhibitor in an oxygen-induced retinopathy
model and showed a significant decrease in retinal neo-
vascularization.5 Adamis and I tested intravitreal monoclonal
antibodies against VEGF (the precursor to Avastin) in the
ischemic retinopathy and iris neovascularization model and
demonstrated complete suppression of neovascularization.2
We also showed that injection of VEGF into normal eyes
was sufficient to produce iris neovascularization and neo-
vascular glaucoma,35 as well as retinal ischemia and micro-
angiopathy,36 in our primate model.
By 1996, we were ready to develop a clinical treatment. We
had extensive data that VEGF played a key role in ischemic
retinopathy in relevant animal models and clinical disease. A
causal role for VEGF in neovascular age-related macular
degeneration (AMD) was not proven, but an association was
evident. Genentech, which had proven inhibitors of VEGF, had
many drugs in their pipeline and were less driven to pursue
ophthalmologic indications. Roche was also a large share-
holder of Genentech and already been down the AMD path
with interferon in the early 1990s.12,27 Having shown no effect
after $18 million was invested in clinical trials, they were not
keen to pursue an AMD indication. This combination of
factors led to 5 years of inconsistent effort at Genentech,
during which they would develop a focused program and then
drop itdor consider licensing to another company then
choose instead to develop anti-VEGF therapy themselves. Not
until several Genentech employees left and licensed an anti-
VEGF aptamer and started Eyetech did Genentech really get
serious about ophthalmic clinical trials.
Our group continued some work with Genentech, investi-
gating the localization of anti-VEGF antibodies. Concerned
that antibodiesmight not cross the retina from the intravitreal
space to affect RPE and choroidal neovascularization (CNV),
we tested whether antibodies given systemically would
extravasate from experimental CNV. Michael Tolentino,
working with Adamis and me, found that intravenous fluo-
resceinated anti-VEGF antibody (essentially Avastin) reached
CNV and persisted in the extravascular space around CNV for
up to 5 days.34
Genentech proceeded with the development of Avastin
and Lucentis, modifying the antibody to increase its affinity
for VEGF and its similarity to human antibodies. Magdalena
Krzystolik, Adamis, and I then showed the efficacy of intra-
vitreal anti-VEGF antibody fragment (essentially Lucentis) in
inhibition of experimental CNV.22 The experiments using
500 mg were published, but the 2 mg dose was also safe and
effective.
Anti-VEGF therapy proceeded into clinical trials. Phase 3
studies were publisheddfirst with Macugen showing efficacy,
but limited visual results.19 The phase 3 studies using Lucentis
showed truly remarkable results, with more than 90% of
s u r v e y o f o p h t h a lm o l o g y 5 9 ( 2 0 1 4 ) 3 6 1e3 6 4 363patients preserving vision, one-third improving by three lines
or more, and more than one-third retaining vision of 20/40 or
better. More recently, the CATT trials showed comparable
vision results between Lucentis and Avastin,8 and VEGF-TRAP
(aflibercept, or Eylea) is an emerging anti-VEGF therapy that
was approved for use in wet AMD in November 2011.20
What about retinal ischemia andmacular edema? After all,
the early studies showed the strongest correlation of VEGF
with retinal ischemia and neovascularization. VEGF does
indeed induce retinal vessel changes and causes breakdown
of the blood retinal barrier.37With the publications ofmultiple
studies in recent years, including the DRCRnet,10,11 the RISE/
RIDE trials,26 and the phase 3 Lucentis trials,6,7 we can
conclude that anti-VEGF therapy has a clear role in diabetic
retinopathy and retinal vein occlusion (RVO). Indeed, Lucentis
was approved by the FDA formacular edema following RVO in
June 2010 and diabetic macular edema in July 2012; Eylea
was approved for macular edema secondary to RVO in
September 2012. In addition, both are being investigated for
a growing list of ocular conditions, including retinopathy of
prematurity, juxtafoveal telangiectasia, radiation retinopathy,
and glaucoma.33 Clearly, VEGF and anti-VEGF approaches are
firmly established in ophthalmology. As Napoleone Ferrara
has stated, although the majority of angiogenesis research
focuses on cancer, the results obtained in noncancerous
disorders (such as AMD, macular edema from RVO, and dia-
betic retinopathy) represent “the most compelling benefits of
anti-angiogenic therapy.”13
It is fun to review the achievements of these researchers and
theirmanycollaborators,butwhat isnext?Tobesuccessful, one
has to mentor successfully, and of course this applies more
broadly than any single ophthalmologydepartment.Within our
department, we strive to continually grow and guide the next
generation of clinician scientists, educators, and researchers.
With our colleagues around the globe, we endeavor to find new
cures forpatientswithblindingeyediseasesothatchildrenborn
today may see throughout their lives.
We are all truly privileged towork in the field that we do. As
Henkind et al wrote in their preface to The Retinal Circulation:38
“What glories lie within the eye.”Disclosures
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